{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T02:34:16Z","timestamp":1763001256830,"version":"3.45.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal Plus: Cardiology Research and Practice"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.ahjo.2023.100259","type":"journal-article","created":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T04:01:58Z","timestamp":1674705718000},"page":"100259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Trends in pharmacotherapy utilization among patients with heart failure with preserved ejection fraction"],"prefix":"10.1016","volume":"26","author":[{"given":"Munaza","family":"Riaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric A.","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David E.","family":"Winchester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingchuan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haesuk","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ahjo.2023.100259_bb0005","doi-asserted-by":"crossref","first-page":"531","DOI":"10.31083\/j.rcm.2020.04.154","article-title":"Epidemiology and pathogenesis of heart failure with preserved ejection fraction","volume":"21","author":"Nair","year":"2020","journal-title":"Rev. Cardiovasc. Med."},{"issue":"9","key":"10.1016\/j.ahjo.2023.100259_bb0010","first-page":"139","article-title":"Heart disease and stroke statistics\u20142020 update: a report from the American Heart Association","volume":"141","author":"VS","year":"2020","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ahjo.2023.100259_bb0015","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11936-018-0623-1","article-title":"Current management and future directions of heart failure with preserved ejection fraction: a contemporary review","volume":"20","author":"Krittanawong","year":"2018","journal-title":"Curr. Treat Options Cardiovasc. Med."},{"issue":"16","key":"10.1016\/j.ahjo.2023.100259_bb0020","first-page":"240","article-title":"2013 ACCF\/AHA guideline for the management of heart failure","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ahjo.2023.100259_bb0025","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1161\/CIR.0000000000000509","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines and the heart failure Society of Amer","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"issue":"2022","key":"10.1016\/j.ahjo.2023.100259_bb0030","first-page":"895","article-title":"AHA\/ACC\/HFSA guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ahjo.2023.100259_bb0035","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1161\/CIRCULATIONAHA.106.628347","article-title":"Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial","volume":"114","author":"Ahmed","year":"2006","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.ahjo.2023.100259_bb0040","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1056\/NEJMoa1510774","article-title":"Isosorbide mononitrate in heart failure with preserved ejection fraction","volume":"373","author":"Redfield","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.ahjo.2023.100259_bb0045","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1161\/CIRCRESAHA.116.309184","article-title":"Inhaled sodium nitrite improves rest and exercise hemodynamics in heart failure with preserved ejection fraction","volume":"119","author":"Borlaug","year":"2016","journal-title":"Circ. Res."},{"issue":"12","key":"10.1016\/j.ahjo.2023.100259_bb0050","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/jama.2013.2024","article-title":"Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial","volume":"309","author":"Redfield","year":"2013","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ahjo.2023.100259_bb0055","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/CIR.0000000000000426","article-title":"Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association","volume":"134","author":"Page","year":"2016","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.ahjo.2023.100259_bb0060","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJM199610103351504","article-title":"Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective randomized amlodipine survival evaluation study group","volume":"335","author":"Packer","year":"1996","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ahjo.2023.100259_bb0065","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1161\/CIRCULATIONAHA.111.080770","article-title":"Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction","volume":"126","author":"SB","year":"2012","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ahjo.2023.100259_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/prp2.676","article-title":"Evaluation of claims-based computable phenotypes to identify heart failure patients with preserved ejection fraction","volume":"8","author":"Cohen","year":"2020","journal-title":"Pharmacol. Res. Perspect."},{"issue":"6","key":"10.1016\/j.ahjo.2023.100259_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cardfail.2010.04.004","article-title":"HFSA 2010 comprehensive heart failure practice guideline","volume":"16","year":"2010","journal-title":"J. Card. Fail."},{"issue":"2","key":"10.1016\/j.ahjo.2023.100259_bb0080","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2018-000782","article-title":"Risk factors for incident heart failure with preserved or reduced ejection fraction, and valvular heart failure, in a community-based cohort","volume":"5","author":"Gong","year":"2018","journal-title":"Open Heart"},{"issue":"6","key":"10.1016\/j.ahjo.2023.100259_bb0085","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.amjmed.2019.10.030","article-title":"Risk factors for heart failure in the community: differences by age and ejection fraction","volume":"133","author":"Chamberlain","year":"2020","journal-title":"Am. J. Med."},{"issue":"4","key":"10.1016\/j.ahjo.2023.100259_bb0090","first-page":"166","article-title":"Real-world treatment patterns, healthcare resource utilization, and costs for patients with newly diagnosed systolic versus diastolic heart failure","volume":"13","author":"Nguyen","year":"2020","journal-title":"Am. Health Drug Benefits"},{"issue":"11","key":"10.1016\/j.ahjo.2023.100259_bb0095","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.amjcard.2020.02.038","article-title":"Trends in treatment for patients hospitalized with heart failure with preserved ejection fraction before and after treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT)","volume":"125","author":"Fudim","year":"2020","journal-title":"Am. J. Cardiol."},{"issue":"13","key":"10.1016\/j.ahjo.2023.100259_bb0100","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.jacc.2018.01.058","article-title":"Angiotensin-converting enzyme inhibitors in hypertension","volume":"71","author":"Mf","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"17","key":"10.1016\/j.ahjo.2023.100259_bb0110","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.ahjo.2023.100259_bb0115","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.ahjo.2023.100259_bb0120","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ahjo.2023.100259_bb0125","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1161\/CIRCHEARTFAILURE.114.001301","article-title":"Calcium Channel blockers and outcomes in older patients with heart failure and preserved ejection fraction","volume":"7","author":"Patel","year":"2014","journal-title":"Circ. Heart Fail."},{"issue":"1","key":"10.1016\/j.ahjo.2023.100259_bb0130","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cardfail.2018.10.014","article-title":"Use of heart failure-exacerbating medications among adults with heart failure","volume":"25","author":"Kneifati-Hayek","year":"2019","journal-title":"J. Card. Fail."},{"issue":"2","key":"10.1016\/j.ahjo.2023.100259_bb0135","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.whi.2004.11.004","article-title":"The association between educational level and risk of cardiovascular disease fatality among women with cardiovascular disease","volume":"15","author":"Lee","year":"2005","journal-title":"Womens Health Issues"},{"issue":"10","key":"10.1016\/j.ahjo.2023.100259_bb0140","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1177\/2047487317705916","article-title":"Effects of education and income on cardiovascular outcomes: a systematic review and meta-analysis","volume":"24","author":"Khaing","year":"2017","journal-title":"Eur. J. Prev. Cardiol."}],"container-title":["American Heart Journal Plus: Cardiology Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666602223000113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666602223000113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T02:31:31Z","timestamp":1763001091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666602223000113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":27,"alternative-id":["S2666602223000113"],"URL":"https:\/\/doi.org\/10.1016\/j.ahjo.2023.100259","relation":{},"ISSN":["2666-6022"],"issn-type":[{"type":"print","value":"2666-6022"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends in pharmacotherapy utilization among patients with heart failure with preserved ejection fraction","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal Plus: Cardiology Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahjo.2023.100259","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100259"}}